Dr. Christian Zeine LGC Standards GmbH July · PDF fileDr. Christian Zeine LGC Standards GmbH Webinar Series 2013 ... impurities should be adequately identified and / or controlled,

Primary / secondary standards in pharmaceutical QC

Dr. Christian ZeineLGC Standards GmbH

Webinar Series 2013July 2013

Quick guide to the webinartools

Slide 2

Topics of today‘s talk

• Close look on:• Close look on:Main reference standard types used in pharmaceuticalanalysisy

– Primary reference standards– Secondary reference standards– Pharmacopoeial reference standards

Impurity reference standards– Impurity reference standards

3

Reference standard types

• Reference standards in general

– Quote from ICH Q6A guideline(downloadable from www.ich.org)

• 2.11 Reference StandardA reference standard, or reference material, is a substance prepared for use as the standard in an assay identification or purity test It should have aas the standard in an assay, identification, or purity test. It should have a quality appropriate to its use. It is often characterized and evaluated for its intended purpose by additional procedures other than those used in routine testing.gFor new drug substance reference standards intended for use in assays, the impurities should be adequately identified and / or controlled, and purity should be measured by a quantitative procedure.

4


• Primary reference standards

– Quote from ICH Q7 guideline(downloadable from www ich org)(downloadable from www.ich.org)

• 11.17 Primary reference standards should be obtained as appropriate for the manufacture of APIs The source of each primary reference standardthe manufacture of APIs. The source of each primary reference standard should be documented. Records should be maintained of each primary reference standard’s storage and use in accordance with the supplier’s recommendations. Primary reference standards obtained from an officially recognised source are normally used without testing if stored under conditions consistent with the supplier’s recommendations.

• 11 18 Where a primary reference standard is not available from an officially• 11.18 Where a primary reference standard is not available from an officially recognized source, an “in-house primary standard” should be established. Appropriate testing should be performed to establish fully the identity and purity of the primary reference standard. Appropriate documentation of this testing should be maintained.

5

Primary/secondaryreference standards

R d d h f i RS ( l• Recommended approach for primary RS (see also EP General text 5.12., paragraph 4-1.)

– Usually purity of >95%– Full characterization and documentation of

• Identity (with several qualitative techniques: NMR, MS, IR, UV/VIS, Elemental analysis, where appropriate X-ray structure analysis)

• Purity (with HPLC => impurity profile)Identify peaks with area percentage >0.1%Maybe check relative response factor of impurity behind peak

continued... continued

6

Primary/secondary reference standards

• Recommended approach for primary RS (continued)Recommended approach for primary RS (continued)

– Full characterization and documentation of• Residual solvents by GC-Headspace methods• Water content by Karl-Fischer titration• Loss on drying (sum of water and residual solvents)y g ( )• Melting point (rough purity/identity information)• Sulphated Ash (inorganic impurities)

• Assay, for primary RSs from purity calculation (with the results from all relevant examinations) plus at least one additional independent method(e.g. qNMR, titration)

7

Certificates – Primary ypharmaceutical reference standards

8


9


10


11


12


13


14


15


16


17

Primary/secondary referencestandards

• Secondary reference standards

– Quote from ICH Q7 guideline(downloadable from www.ich.org)(downloadable from www.ich.org)

• 11.19 Secondary reference standards should be appropriately prepared, identified, tested, approved, and stored. The suitability of each batch ofidentified, tested, approved, and stored. The suitability of each batch of secondary reference standard should be determined prior to first use by comparing against a primary reference standard. Each batch of secondary reference standard should be periodically requalified in

d ith itt t laccordance with a written protocol.

18

Secondary pharmaceutical y preference standards – Certificates

19


20


21


• Pharmacopoeial reference standards(BP EP USP and others)(BP, EP, USP and others)

– Are „special“ primary standardsAre „special primary standards• From an officially recognised source• Can be used without further testing• Are widely acceptedAre widely accepted

– But ...• For claiming official status must be used according• For claiming official status, must be used according

to the use mentioned in the monographs• Otherwise, responsibility lies with user, and pharmacopoeia

commissions reject responsibilitycommissions reject responsibility

22


Ph i l f d d• Pharmacopoeial reference standards,restricted use, quotations

– USP General Chapter <11> :• "They (USP Reference Standards) are explicitly required in many

Pharmacopeial assays and tests and are provided solely for such use. Assessment of the suitability for use in other application(s) rests with thepurchaser."

– General text 5.12., Ph. Eur.:• „EPCRS. A substance (EP CRS) ... intended for use as stated in a

monograph of the Ph Eurmonograph ... of the Ph. Eur. ... Reference standards are ... suitable for their intended purpose; they are not necessarily suitable for other purposes. ... For any purposes other than that for which it has been established, itssuitability ... has to be fully demonstrated." 23


I it f t d d• Impurity reference standards

– Not much guidance from authorities here– Not much guidance from authorities here

• ICH Q3A:Reference standards used in the analytical procedures for control of„Reference standards used in the analytical procedures for control of

impurities should be evaluated and characterised according to their intended uses.”

• German authority BfArM (“Randnummerndokument”), translated“Impurity standards are used for purity tests and during method development and validation of those tests. Identity must be ensured and purity and assay must be defined ”must be defined.

– The following certificate of analysis is normally l t d ( l t d l t )always accepted (see also case study later)

24

CofA: Impurity RS

25

CofA: Impurity RS

26

CofA: Impurity RS

27

CofA: Impurity RS

28

CofA: Impurity RS

29

CofA: Impurity RS

30

CofA: Impurity RS

31

Differences between referencestandards and research materials

• Recent case: Client informed us that authorities wereaccepting our impurity standard because of the CofAaccepting our impurity standard because of the CofA

– Client: German subsidiary of one of World‘s top 3 genericClient: German subsidiary of one of World s top 3 genericmanufacturers

– Also client information: Not all of their materialswere accepted because of scarce analytical informationwere accepted, because of scarce analytical informationon CofA

• Be aware of the difference between impurity standardand research material, for example CofA

32

CofA: Research material

33

CofA: Research material

34

Differences between referencestandards and research materials

• Apart from client‘s experience, also to be awarep p ,of the following:

– CofA is relevant for the corresponding use• I.e. a research material with poor purity/assay information not suitable for

quantitative purposes• Like determination of API‘s assay figures or impurity level

• For both applications high risks of overestimation of analyte, can result in ...

• ... releasing products of insufficient (API) quality into market• ... overestimating impurity => rejecting batches actually fine

to be released

35

Summary of today‘s talk

• Close look on:Main reference standard types used in pharmaceuticalanalysisanalysis

– Primary reference standardsy• Very detailed characterisation

– Secondary reference standardsCompared to primary standards• Compared to primary standards

– Pharmacopoeial reference standards• Special primary standards (for official applications)

– Impurity reference standards• Detailed characterisaton relevant for exact impurity level• Be aware of the differences between a standard and a research material

36

Closing remarksg

• LGC Standard is part of LGC group• LGC Standard is part of LGC group

• S&T section of LGC acts as NMI for chemical andS&T section of LGC acts as NMI for chemical and biochemical measurement in the UK (comparable to NIST in the US))

37

Closing remarksg

• Manufacturing of pharmaceutical reference materials• Manufacturing of pharmaceutical reference materials– For APIs and impurities, over 3,000 standards– Metal impurity materials (suitableeta pu ty ate a s (su tab e

for ICP-OES and ICP-MS applications)– Constantly new developments

L h f i t d d t l d t i O t b 2013!• Launch of primary standard catalogue products in October 2013!

– ISO 34 and ISO 17025 accredited

• Contract servicesContract services– Custom synthesis (for RSs)– Custom analysis– Characterisation of customer material– Customised packaging and storage

38

Closing remarks

• Further webinars in July/August, registration possible under http://pharma.lgcstandards.com/p p g– On website, look under ‘Events’

Always on a Thursday, always 10.30 – 11.15• 25th of July 2013:• 25th of July 2013:

Seven truths of impurities and their reference standards, Part 1• 1st of August 2013:

Seven truths of impurities and their reference standards, Part 2Seven truths of impurities and their reference standards, Part 2

39

QUESTIONS?

Now, or to [email protected]@ g

40

Documents

Dr. Christian Zeine LGC Standards GmbH July · PDF fileDr. Christian Zeine LGC Standards GmbH Webinar Series 2013 ... impurities should be adequately identified and / or controlled,